WolverHeme Happy Hour

In this episode, Anthony, Bernie, and Lydia are joined by a former patient, Madeline B, to talk about her ALL treatment journey. Drawing inspiration from Taylor Swift's upcoming concert and heartfelt ballad ("All Too Well"), this episode tackles some of the unique challenges, emotions, and considerations that come with helping adolescents and young adults (AYA) with treatment for acute leukemia. This is a must-listen for anyone taking care of AYA patients!

In this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in FLT3-ITD+ AML? Have we made a "Quantum Leap" in the treatment of these patients? Listen for a fun-filled discussion of the data! Notable References: QUANTUM-First Study: https://pubmed.ncbi.nlm.nih.gov/37116523/ WolverHeme Episode 8 (Pulling the Goalie on FLT3 Inhibitor Use in AML): https://podcasters.spotify.com/pod/show/wolverheme/episodes/Episode-8-Pulling-the-Goalie-on-FLT3-Inhibitor-Use-in-AML---A-Discussion-with-Dr--Dale-Bixby-e1r6tqt/a-a8tthkc

Blinatumomab - it's Oprah's new favorite drug! On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen and find out! ECOG1910 Late-Breaking Abstract: https://ash.confex.com/ash/2022/webprogram/Paper171751.html 

In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain. Relevant Articles: Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/ Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/ Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/ Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/ Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/ CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/

In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?  Olutasidenib Phase I - Watts, et al. Lancet. 2023: https://pubmed.ncbi.nlm.nih.gov/36370742/ Olutasidenib Phase II ASH Abstract: https://ash.confex.com/ash/2022/webprogram/Paper167330.html Ivosidenib Phase I escalation/expansion - Dinardo, et al. NEJM. 2018: https://pubmed.ncbi.nlm.nih.gov/29860938/ Design of olutasidenib and other IDH inhibitors: https://pubmed.ncbi.nlm.nih.gov/31971798/ and https://pubmed.ncbi.nlm.nih.gov/36091829/ Episode 5 of WolverHeme Happy Hour (for background on IDH Inhibitors and frontline data): https://open.spotify.com/episode/4eNXjuGEFFRWTFJF0zsuMw?si=9bd0ae0a488e44ba 

In this episode, we are joined by the legendary hematologist and rock star - Dr. Aaron Goodman - aka "Papa Heme"! We discuss which ASH abstracts might be practice changing and which simply don't make the cut. Stay tuned for an entertaining and very educational episode! 

In this episode, Anthony and Bernie begin to recap some interesting studies presented at ASH, starting with a discussion the results of the "Dauno-Double" Trial. Should it change practice? Dauno-Double Trial: https://ash.confex.com/ash/2022/webprogram/Paper157126.html Dr. Todd Lee breaking down the non-inferiority numbers: https://twitter.com/DrToddLee/status/1600662377250586627?s=20&t=RdIhJJpMG-G_oPUSH2u2mw 

In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views! REFERENCES Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/ RATIFY Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1614359 QUANTUM-FIRST: https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676 ODAC Review of Quantum-R (quizartinib): https://www.fda.gov/media/124896/download ELN 2022: https://pubmed.ncbi.nlm.nih.gov/35797463/ WHO Myeloid 2022: https://pubmed.ncbi.nlm.nih.gov/35732831/ Sorafenib Maintenance (RCT China): https://pubmed.ncbi.nlm.nih.gov/32791048/ SorMAIN: https://pubmed.ncbi.nlm.nih.gov/32673171/ RADIUS (midostaurin maintenance): https://pubmed.ncbi.nlm.nih.gov/33288862/ LACEWING Trial: https://pubmed.ncbi.nlm.nih.gov/35917453/ HMA/Ven pooled FLT3: https://pubmed.ncbi.nlm.nih.gov/35063965/ Ven/Aza/Gilteritinib ASH 2022: https://ash.confex.com/ash/2022/webprogram/Paper157210.html UK NCRI AML 17 Flt3 analysis: https://pubmed.ncbi.nlm.nih.gov/27268085/

After a refreshing break, the hosts dive into the fascinating pharmacology behind major AML therapies. They discuss the iconic '3 plus 7' chemotherapy regimen and its lasting impact. Historical insights on anthracyclines reveal their evolution and crucial studies on effectiveness. The conversation also covers the unique journey of cytarabine, exploring its origins and complex administration challenges. Lastly, advancements in purine analogs shed light on new treatment strategies, especially for older patients. Beverages and personal anecdotes add a fun twist to the serious topics!

In this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase activity levels (per Papa Heme request!). For those who don't know (and maybe aren't as nerdy as we are), the title is a reference to the 1964 film Dr. Strangelove!